Selumetinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), G-BA (Germany) and ZIN (Netherlands) recommended or restricted selumetinib, while AOTMIT (Poland), CIPM (Spain) and CONITEC (Brazil), among others, did not recommend it.
Assessment has run over 5 years, from 13 May 2021 at AWMSG (Wales) to 7 May 2026 at G-BA (Germany).
PBAC (Australia) changed its position: not recommended in 2022, recommended by 2024, after a resubmission.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 12 of 18 records date from 2023 or later.
Against its own class, selumetinib is an outlier: 38% of its decisive outcomes were positive, where molecules sharing ATC class L01E average 75%.
3 distinct indication wordings are recorded for selumetinib by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 18 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess selumetinib, on 13 May 2021; G-BA (Germany) did not open a file until 7 May 2026 — a wide spread of 5 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 6 years in total.
4 of the 14 agencies here assessed selumetinib more than once, G-BA (Germany) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
selumetinib has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for selumetinib reads 10 not recommended, 5 recommended, 1 restricted and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 7 May 2026 | Koselugo — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| NYE METODER (Norway) | 18 Jan 2026 | Behandling av symptomatiske inoperable pleksiforme nevrofibromer (PN) hos pediatriske pasienter med nevrofibromatose typ… | not introduced | source |
| CONITEC (Brazil) | 26 Sep 2025 | Tratamento de pacientes pediátricos com neurofibromatose tipo 1 (NF1) e neurofibroma plexiforme inoperável sintomático. | not incorporated | source |
| TLV (Sweden) | 12 Jul 2024 | Koselugo ingår inte i högkostnadsskyddet | rejection or exclusion | source |
| PBAC (Australia) | 2024 | Neurofibromatosis type 1 (NF1) | Recommended | source |
13 further decisions for selumetinib, across 12 agencies, are not shown here. They include the most recent record on file, 7 May 2026 from G-BA (Germany); its outcome is in the subscriber dataset. They link to 11 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 18 decisions for selumetinib from 14 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.